Extensive age-dependent loss of antibody diversity in naturally short-lived turquoise killifish

Abstract

Aging individuals exhibit a pervasive decline in adaptive immune function, with important implications for health and lifespan. Previous studies have found a pervasive loss of immune-repertoire diversity in human peripheral blood during aging; however, little is known about repertoire aging in other immune compartments, or in species other than humans. Here, we perform the first study of immune-repertoire aging in an emerging model of vertebrate aging, the African turquoise killifish (Nothobranchius furzeri). Despite their extremely short lifespans, these killifish exhibit complex and individualized heavy-chain repertoires, with a generative process capable of producing millions of distinct productive sequences. Whole-body killifish repertoires decline rapidly in within-individual diversity with age, while between-individual variability increases. Large, expanded B-cell clones exhibit far greater diversity loss with age than small clones, suggesting important differences in how age affects different B cell populations. The immune repertoires of isolated intestinal samples exhibit especially dramatic age-related diversity loss, related to an elevated prevalence of expanded clones. Lower intestinal repertoire diversity was also associated with transcriptomic signatures of reduced B-cell activity, supporting a functional role for diversity changes in killifish immunosenescence. Our results highlight important differences in systemic vs. organ-specific aging dynamics in the adaptive immune system.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided. The raw data used in these analyses are available via NCBI (BioProject accession PRJNA662612). Processed data and code are freely available at https://github.com/willbradshaw/killifish-igseq/

The following data sets were generated

Article and author information

Author details

  1. William John Bradshaw

    Evolutionary and Experimental Biology of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany
    Competing interests
    No competing interests declared.
  2. Michael Poeschla

    Evolutionary and Experimental Biology of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany
    Competing interests
    No competing interests declared.
  3. Aleksandra Placzek

    Evolutionary and Experimental Biology of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany
    Competing interests
    No competing interests declared.
  4. Samuel Kean

    Evolutionary and Experimental Biology of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany
    Competing interests
    No competing interests declared.
  5. Dario Riccardo Valenzano

    Evolutionary and Experimental Biology of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany
    For correspondence
    dvalenzano@age.mpg.de
    Competing interests
    Dario Riccardo Valenzano, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8761-8289

Funding

Max Planck Society (Valenzano lab budget)

  • Dario Riccardo Valenzano

DFG (CRC 1310)

  • Dario Riccardo Valenzano

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Bradshaw et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,822
    views
  • 229
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. William John Bradshaw
  2. Michael Poeschla
  3. Aleksandra Placzek
  4. Samuel Kean
  5. Dario Riccardo Valenzano
(2022)
Extensive age-dependent loss of antibody diversity in naturally short-lived turquoise killifish
eLife 11:e65117.
https://doi.org/10.7554/eLife.65117

Share this article

https://doi.org/10.7554/eLife.65117

Further reading

    1. Genetics and Genomics
    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics
    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.